Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, α-fluoro-β-ureidopropionic acid and α-fluoro-β-alanine in human plasma

被引:27
作者
Chavani, Ottiniel [1 ]
Jensen, Berit Packert [1 ]
Strother, R. Matthew [2 ]
Florkowski, Christopher M. [1 ]
George, Peter M. [1 ]
机构
[1] Canterbury Hlth Labs, Christchurch, New Zealand
[2] Christchurch Hosp, Oncol, Christchurch, New Zealand
关键词
LC-MS/MS; UH2/U; FUH2/5-FU; FUPA; F beta AL; Therapeutic drug monitoring; DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; MS/MS METHOD; DIHYDROURACIL/URACIL RATIO; GENETIC-REGULATION; COLORECTAL-CANCER; ANTICANCER AGENTS; ADVANCED HEAD; NECK-CANCER; HPLC-MS/MS; TOXICITY;
D O I
10.1016/j.jpba.2017.04.055
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The plasma 5,6-dihydrouracil/uracil (UH2/U) ratio is a possible phenotypic marker of dihydropyrimidine dehydrogenase (DPD) activity, hence an index of 5-fluorouracil (5-FU) response and toxicity. Studies have re -affirmed the value of 5 -FU and 5,6-dihydro-5-fluorouracil (FUH2) for therapeutic drug monitoring (TDM). However, FUH2 has limited stability in plasma, necessitating expedited plasma separation and freezing, where routine compliance may not be easy. The metabolites alpha-fluoro-beta-ureidopropionic acid (FUPA) and alpha-fluoro-beta-alanine (F beta AL) are stable in plasma and are probable candidates for TDM. This paper describes development, validation and application of an LC-MS/MS assay quantifying U, UH2, 5-FU, FUH2, FUPA and F beta AL in human plasma. Extraction was by salt-assisted liquid-liquid extraction (LLE) in two-stages with pH adjustment. The supernatants were mixed, dried and reconstituted. Analytes were resolved on the Luna PFP (2) (150 x 2.00 mm, 3 mu) column by gradient elution and analyzed by tandem mass spectrometry via electrospray ionisation in positive polarity. The analytical response was linear (r(2) >= 0.99) in the concentration (ng/mL) ranges: 50-10 000 for F beta AL and FUH2, 50-5 000 for FUPA, 50-100 000 for 5 -FU, 5-200 for U and 10-400 for UH2. Within-and between-run accuracy and precision were <= 10.2% and <= 9.8% respectively across the QC range and inclusive of LLOQ. The internal standard (IS) normalised matrix effects were within 93-112% with CV of <= 9.7% and normalised recoveries were within 91-107% with CV of <= 9.8%. This robust assay was successfully applied to samples from rectal and colorectal cancer patients (n = 10) on 5 -FU. Deviations <= 2.0% from the mean values were observed when incurred samples were reanalysed. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:125 / 135
页数:11
相关论文
共 38 条
[1]   5-Fluorouracil derivatives: a patent review [J].
Alvarez, Pablo ;
Antonio Marchal, Juan ;
Boulaiz, Houria ;
Carrillo, Esmeralda ;
Velez, Celia ;
Rodriguez-Serrano, Fernando ;
Melguizo, Consolacion ;
Prados, Jose ;
Madeddu, Roberto ;
Aranega, Antonia .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (02) :107-123
[2]   Simultaneous gas chromatographic mass spectrophotometric determination of alpha-fluoro-beta-alanine and 5-flaorouracil in plasma [J].
Anderson, D ;
Kerr, DJ ;
Blesing, C ;
Seymour, LW .
JOURNAL OF CHROMATOGRAPHY B, 1997, 688 (01) :87-93
[3]   Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001 [J].
Baker, SD ;
Verweij, J ;
Rowinsky, EK ;
Donehower, RC ;
Schellens, JHM ;
Grochow, LB ;
Sparreboom, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (24) :1883-1888
[4]   EFFECT OF PLYOMETRIC TRAINING ON SWIMMING BLOCK START PERFORMANCE IN ADOLESCENTS [J].
Bishop, Daniel C. ;
Smith, Russell J. ;
Smith, Mark F. ;
Rigby, Hannah E. .
JOURNAL OF STRENGTH AND CONDITIONING RESEARCH, 2009, 23 (07) :2137-2143
[5]   5-fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency [J].
Boisdron-Celle, M. ;
Remaud, G. ;
Traore, S. ;
Poirier, A. L. ;
Gamelin, L. ;
Morel, A. ;
Gamelin, E. .
CANCER LETTERS, 2007, 249 (02) :271-282
[6]   LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients [J].
Buechel, Barbara ;
Rhyn, Peter ;
Schuerch, Stefan ;
Buehr, Claudia ;
Amstutz, Ursula ;
Largiader, Carlo R. .
BIOMEDICAL CHROMATOGRAPHY, 2013, 27 (01) :7-16
[7]   A Rapid HPLC-ESI-MS/MS Method for Determination of Dihydrouracil/Uracil Ratio in Plasma: Evaluation of Toxicity to 5-Flurouracil in Patients With Gastrointestinal Cancer [J].
Cesar, Isabela Costa ;
Cunha-Junior, Geraldo F. ;
Duarte Byrro, Ricardo M. ;
Vaz Coelho, Luiz Gonzaga ;
Pianetti, Gerson A. .
THERAPEUTIC DRUG MONITORING, 2012, 34 (01) :59-66
[8]   A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity [J].
Ciccolini, J ;
Mercier, C ;
Blachon, MF ;
Favre, R ;
Durand, A ;
Lacarelle, B .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (04) :307-315
[9]   Validation of an Ultra-High Performance Liquid Chromatography Tandem Mass Spectrometric Method for Quantifying Uracil and 5,6-Dihydrouracil in Human Plasma [J].
Coudore, Francois ;
Roche, Denis ;
Lefeuvre, Sandrine ;
Faussot, Delphine ;
Billaud, Eliane M. ;
Loriot, Marie-Anne ;
Beaune, Philippe .
JOURNAL OF CHROMATOGRAPHIC SCIENCE, 2012, 50 (10) :877-884
[10]   Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry [J].
Deenen, Maarten J. ;
Rosing, Hilde ;
Hillebrand, Michel J. ;
Schellens, Jan H. M. ;
Beijnen, Jos H. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2013, 913 :30-40